H3 Biomedicine launches with $200M from Eisai
Eisai Inc. launched on Thursday a wholly owned research and development subsidiary in Cambridge called H3 Biomedicine Inc. that will focus on personalized cancer medicines based on cancer genetics and chemistry advances. Eisai, the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., has pledged up to $200 million in research funding, plus more for clinical […]